UroGen Pharma (URGN) Enterprise Value (2016 - 2026)

UroGen Pharma (URGN) has reported Enterprise Value for 11 consecutive years, with -$140.3 million the latest figure, recorded in Q1 2026.

• Quarterly Enterprise Value rose 28.39% year-over-year to -$140.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$140.3 million (up 28.39% YoY) and the FY2025 annual result came in at -$120.5 million, up 49.11% from the prior year.
• Enterprise Value declined to -$140.3 million in Q1 2026 per URGN's latest filing, from -$120.5 million in the prior quarter.
• Over the last five years, Enterprise Value for URGN reached as high as -$47.3 million in Q2 2023 and fell as low as -$249.6 million in Q3 2024.
• A 5-year average of -$143.4 million and a median of -$137.0 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2023 — Enterprise Value soared 52.32% — and 2024, when it tumbled 409.67%.
• Year by year, Enterprise Value stood at -$100.0 million in 2022, then plunged by 37.02% to -$137.0 million in 2023, then tumbled by 72.8% to -$236.7 million in 2024, then jumped by 49.11% to -$120.5 million in 2025, then retreated by 16.45% to -$140.3 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$140.3 million, -$120.5 million, and -$127.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.